Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Placebo-controlled, Phase 3b Study

Next Previous
Trial Profile

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Placebo-controlled, Phase 3b Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Macitentan (Primary) ; Selexipag (Primary) ; Tadalafil (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms TRITON
  • Sponsors Actelion Pharmaceuticals

Most Recent Events

  • 05 Oct 2021 Results assessing efficacy and safety of initial triple oral therapy with macitentan, tadalafil, and selexipag compared with initial double oral therapy with macitentan and tadalafil innaive newly-diagnosed,with PAH published in the Journal of the American College of Cardiology
  • 30 Aug 2021 According to a Janssen media release, post hoc analysis from TRITON and GRIPHON presented in as an oral presentation at ESC Congress 2021.
  • 30 Aug 2021 Results of post hoc analysis from TRITON and GRIPHON studies presented Janssen media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top